Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
APY0201
Cat. No.:
0225LY-0779
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
APY0201 is a highly specific, ATP-competitive inhibitor of PIKfyve (IC50: 5.2 nM) that halts the conversion of phosphatidylinositol 3-phosphate (PtdIns3P) to PtdIns(3,5)P2.
Synonym:
1232221-74-7; (E)-4-(5-(2-(3-methylbenzylidene)hydrazinyl)-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)morpholine; N-[(E)-(3-methylphenyl)methylideneamino]-7-morpholin-4-yl-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-5-amine; 4-(5-(2-(3-Methylbenzylidene)hydrazinyl)-2-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-7-yl)morpholine
CAS No.:
1232221-74-7
Compound CID:
56927660
Formula:
C23H23N7
Formula Weight:
413.48
Specification
Targets&IC50:
PIKfyve: 5.2 nM
Relative Density:
1.33 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
APY0201 can be used in virology studies to investigate the potent inhibition of PIKfyve and its role in blocking infectious viral pathways.
Library Information
Target:
PIKfyve
Receptor:
PIKfyve
Pathways:
Immunology/Inflammation; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-11
Plate Location:
a8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
2mM DMSO
DMSO Max Solubility:
1 mg/mL; 2.42 mM





